# US 11,896,571 B2 · Methods for increasing oral osteogenesis using lipoxin A4 (LXA4) and its analogs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,571 B2
- Document ID: US11896571B2
- Status: Granted
- Kind: B2
- Application number: 16/594,602
- Filed: 2019-10-07
- Published: 2020-05-07
- Granted: 2024-02-13
- Earliest claimed: 2013-02-21
- Assignees: Forsyth Dental Infirmary for Children
- Applicants: Forsyth Dental Infirmary for Children
- Inventors: Thomas E. Van Dyke; Hatice Hasturk; Alpdogan Kantarci
- Web page: https://patentgrep.com/patent/US11896571B2

## CPC

- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0063: {Periodont}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides methods for increasing oral osteogenesis using LXA4 and its analogs. Methods are also provided for treating or preventing oral disorders that would benefit from increased oral osteogenesis using LXA4 and its analogs.

## Claims

### Claim 1

A method of increasing oral osteogenesis in a subject afflicted with a periodontal disease, the method comprising topically administering a therapeutically effective amount of a lipoxin A4 (LXA4) analog to the oral cavity of the subject,
wherein the LXA4 analog is 9,12 benzo-LXA4, and
wherein the 9,12 benzo-LXA4 increases oral osteogenesis in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the periodontal disease is selected from the group consisting of periodontitis, dental plaque-induced gingival diseases; chronic (previously adult) periodontitis; aggressive periodontitis (formerly early-onset, prepubertal, juvenile or rapidly progressive periodontitis); necrotizing periodontal diseases; abscesses of the periodontium; post-operative bacterial infections, alveolar bone loss, and gingivitis.

### Claim 3 (depends on 1)

The method of claim 1, wherein the 9,12 benzo-LXA4 is formulated in a pharmaceutically acceptable carrier.

### Claim 4 (depends on 3)

The method of claim 3, wherein the pharmaceutically acceptable carrier is selected from the group consisting of gels, mouth rinses, toothpastes, dentifrice, buccal patch, dental fiber, dental tape, chewing gum, food additives, lozenges, tablet, and chewable capsule.

### Claim 5 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of 9,12 benzo-LXA4 is an amount that increases oral bone growth and/or reduces oral bone reabsorption.

### Claim 6 (depends on 1)

The method of claim 1, further comprising administering to the subject at least one additional agent that treats periodontal disease.

### Claim 7 (depends on 6)

The method of claim 6, wherein the additional agent is selected from the group consisting of anti-inflammatory agents and antimicrobial agents.

### Claim 8 (depends on 3)

The method of claim 3, wherein the pharmaceutically acceptable carrier is an intraoral delivery device.

### Claim 9 (depends on 1)

The method of claim 1, wherein the LXA4 analog is encapsulated in a nanoparticle of biologic or synthetic origin.

### Claim 10 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of 9,12 benzo-LXA4 is an amount that increases oral osteogenesis by at least 10% relative to not administering the LXA4 analog.

### Claim 11 (depends on 1)

The method of claim 1, wherein the administering is to a subject undergoing periodontal flap surgery.

### Claim 12 (depends on 1)

The method of claim 1, wherein the administering is to a subject has undergone periodontal flap surgery.

### Claim 13 (depends on 11)

The method of claim 11, further comprising additionally administering a therapeutically effective amount of 9,12 benzo-LXA4 to the subject one or more times after periodontal flap surgery completion.